Gastrointestinal cancers are a leading cause of cancer morbidity and mortality worldwide
with 4.2 million new cases and 3.2 million deaths estimated in 2020. Despite the advances …

Gastrointestinal (GI) cancer constitutes a highly lethal entity among malignancies in the last
decades and is still a major challenge for cancer therapeutic options. Despite the current …

Abstract In December 2022 the US Food and Drug Administration (FDA) removed the
requirement that drugs in development must undergo animal testing before clinical …

Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) constitute highly
malignant forms of primary liver cancers. Hepatocellular and bile duct carcinogenesis is a …

The tumor microenvironment can inhibit the efficacy of cancer therapies through
mechanisms such as poor trafficking and exhaustion of immune cells. Here, to address this …

While gastrointestinal tumors remain a multifactorial and prevalent group of malignancies
commonly treated surgically in combination with chemotherapy and radiotherapy …

Colorectal cancer (CRC) constitutes the third most frequently reported malignancy in the
male population and the second most common in women in the last two decades. Colon …

Abstract Purpose While Fear of progression (FoP) is a natural reaction in cancer, elevated
FoP can impact life quality and social function. Our study aims to explore how illness …

The complex immune system of the liver has a major role in tumor surveillance, but also
partly explains why current immune therapies are poorly effective against liver cancers …

Inflammation, as a complex immunopathological process, is the organism's natural defense
response against harmful, foreign, and destructive immune or non-immune factors. It is the …